4.7 Article

Expression and regulation of IFNα/β receptor in IFNβ-treated patients with multiple sclerosis

Journal

NEUROLOGY
Volume 71, Issue 24, Pages 1940-1947

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1212/01.wnl.0000327340.50284.8d

Keywords

-

Funding

  1. Fondazione Italiana Sclerosi Multipla [2007/R/6]
  2. Fondazione per la Ricerca Biomedica
  3. ONLUS
  4. S. Luigi Gonzaga ONLUS
  5. European Commission [018926]

Ask authors/readers for more resources

Background: The cytokine interferon beta (IFN beta) is successfully used in the treatment of multiple sclerosis (MS), although there is a high degree of variability in the response. A common mechanism involved in the modulation of responsiveness to cytokines is represented by regulation of their receptor expression through autocrine ligand-mediated loops. The present study is aimed at investigating the regulation of IFN alpha/beta receptor (IFNAR) during IFN beta therapy in patients with MS and at correlating it with the biologic responsiveness to the cytokine. Methods: Quantitative PCR measurements of IFNAR-1 and the three IFNAR-2 isoforms were performed in 141 patients after short-term and long-term treatment. Patients were also regularly screened for anti-IFN beta neutralizing antibodies (NAbs). IFN-inducible myxovirus resistance protein A messenger RNA was used as an indicator of bioactivity. Results: Pretreatment levels of IFNAR-2 in patients were lower overall than in controls (p = 0.038), and high levels correlated with greater bioactivity. Upon prolonged treatment, NAb-negative patients displayed a state of decreased transmembrane IFNAR-2 expression (p <= 0.025), whereas levels of soluble IFNAR-2 were slightly increased (p < 0.0001). The presence of NAbs reversed these effects (p <= 0.0056). In NAb-positive patients, pretreatment expression levels of both transmembrane IFNAR-2 isoforms were significantly lower than in NAb-negative patients (p <= 0.0089). Conclusions: Findings show that interferon-alpha/beta receptor (IFNAR)-2 isoforms are important regulators of the responsiveness to endogenous and systemically administered interferon beta (IFN beta). They show a dual action, agonistic and antagonistic, that influences both the magnitude and the nature of the biologic response to IFN beta. Levels of IFNAR-2 are regulated with the aim of keeping the body in a state of equilibrium, even when nonphysiologic stimuli are present.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available